

ELISA PRODUCT INFORMATION & MANUAL

Human Complement Factor B ELISA Kit (Colorimetric)

NBP2-60564

Enzyme-linked Immunosorbent Assay for quantitative detection. For research use only.

Not for diagnostic or therapeutic procedures.

www.novusbio.com - P: 303.730.1950 - P: 888.506.6887 - F: 303.730.1966 - technical@novusbio.com

Novus kits are guaranteed for 6 months from date of receipt

Assay Summary

Step 1. Add 50 μl of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μ l of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 25 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key



Consult instructions for use.

Assay Template

| 12 | | | | | | | | |
|----|---|---|---|---|---|---|---|---|
| 11 | | | | | | | | |
| 10 | | | | | | | | |
| 6 | | | | | | | | |
| ∞ | | | | | | | | |
| 7 | | | | | | | | |
| 9 | | | | | | | | |
| .c | | | | | | | | |
| 4 | | | | | | | | |
| ю | | | | | | | | |
| 2 | | | | | | | | |
| 1 | | | | | | | | |
| | Ą | В | 3 | Q | 3 | Ŧ | 9 | I |

AssayMax™ Human Complement Factor B ELISA Kit

Catalog No. NBP2-60564
Sample insert for reference use only

Introduction

Complement factor B (CFB) is a component of the alternative pathway of complement activation. The zymogen circulates in the blood as a 93 kDa single chain glycoprotein with 739 amino acids (1-3). In the presence of C3b, it is cleaved by factor D into a 30 kDa N-terminal non-catalytic Ba fragment and a 63 kDa C-terminal catalytic Bb fragment. The active subunit Bb associates with C3b to form the alternative pathway C3 convertase. Human CFB plays a major role in the initiation of the alternative pathway and in the amplification of C3 cleavage. The polymorphism of CFB influences C3 convertase formation and is associated with age-related macular degeneration and polypoidal choroidal vasculopathy (4-5).

Principle of the Assay

The AssayMax™ Human Complement Factor B ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of CFB in human plasma, serum, milk, saliva, CSF, cell culture, cell lysate, and tissue samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures human CFB in approximately 4 hours. A polyclonal antibody specific for human CFB has been pre-coated onto a 96-well microplate with removable strips. CFB in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human CFB, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for Research Use Only and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.

- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human Complement Factor B Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human CFB.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human Complement Factor B Standard: Human CFB in a buffered protein base (182 ng, lyophilized).
- Biotinylated Human Complement Factor B Antibody (50x): A 50-fold concentrated biotinylated polyclonal antibody against human CFB (120 μl).
- EIA Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.
- Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)

Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

- Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. A 16000-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- Serum: Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. A 16000-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples should be aliquoted to limit repeated freeze-thaw cycles and stored at -80°C for up to 3 months. When needed, the frozen sample should be thawed rapidly in a water bath at 37°C and immediately placed on ice until use to prevent complement activation.
- Milk: Collect milk using sample tube. Centrifuge samples at 800 x g for 10 minutes. A 50-fold sample dilution is suggested into EIA Diluent or within the range of 5x – 500x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Saliva: Collect saliva using sample tube. Centrifuge samples at 800 x g for 10 minutes. The sample is suggested for use at 1x or within the range of 2x 20x into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- **CSF:** Collect cerebrospinal fluid (CSF) using sample pot. Centrifuge samples at 3000 x g for 10 minutes. A 2-fold sample dilution is suggested into EIA Diluent or within the range of 1x 40x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.
- Cell Culture Supernatant: Centrifuge cell culture media at 1500 rpm for 10 minutes at 4°C to remove debris and collect supernatant. If necessary, dilute samples into EIA Diluent; user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C. Avoid repeated freeze-thaw cycles.
- Cell Lysate: Rinse cell with cold PBS and then scrape the cell into a tube with 5 ml of cold PBS and 0.5 M EDTA. Centrifuge suspension at 1500

rpm for 10 minutes at 4°C and aspirate supernatant. Resuspend pellet in ice-cold Lysis Buffer (PBS, 1% Triton X-100, protease inhibitor cocktail). For every 1 x 10 6 cells, add approximately 100 μ l of ice-cold Lysis Buffer. Incubate on ice for 60 minutes. Centrifuge at 13000 rpm for 30 minutes at 4°C and collect supernatant. If necessary, dilute samples into EIA Diluent; user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C. Avoid repeated freeze-thaw cycles.

Tissue: Extract tissue samples with 0.1 M phosphate-buffered saline (pH 7.4) containing 1% Triton X-100 and centrifuge at 14000 x g for 20 minutes. Collect the supernatant and measure the protein concentration. If necessary, dilute samples into EIA Diluent; user should determine optimal dilution factor depending on application needs. Store remaining extract at -80°C. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

| | Guidelines for Dilutions of 100-fold or Greater | | | | |
|----------|-----------------------------------------------------------------------------------------------------------------------------------|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| | (for reference only; please follow the | inser | t for specific dilution suggested) | | |
| | 100x | | 10000x | | |
| A) | 4 μl sample : 396 μl buffer (100x) = 100-fold dilution Assuming the needed volume is less than or equal to 400 μl. | A) B) | 4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution Assuming the needed volume is less than or equal to 400 μl. | | |
| 1000x | | | 100000x | | |
| A) B) | 4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution Assuming the needed volume is less than | A) B) C) | 4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution Assuming the needed volume is less than | | |
| | or equal to 240 µl. | | or equal to 240 µl. | | |

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- EIA Diluent Concentrate (10x): Dilute the EIA Diluent Concentrate 10fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any

- precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved. Store for up to 30 days at 2-8°C.
- Human Complement Factor B Standard: Reconstitute the Human Complement Factor B Standard (182 ng) with 1.3 ml of EIA Diluent to generate a 140 ng/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (140 ng/ml) 2-fold with equal volume of EIA Diluent to produce 70, 35, 17.5, 8.75, 4.375, and 2.188 ng/ml solutions. EIA Diluent serves as the zero standard (0 ng/ml). Aliquot remaining stock solution to limit repeated freeze-thaw cycles. This solution should be stored at -20°C and used within 10 days.

| Standard Point | Dilution | [CFB] (ng/ml) |
|-------------------|--------------------------------|------------------|
| P1 | 1 part Standard (140 ng/ml) | 140 |
| P2 | 1 part P1 + 1 part EIA Diluent | 70 |
| Р3 | 1 part P2 + 1 part EIA Diluent | 35 |
| P4 | 1 part P3 + 1 part EIA Diluent | 17.5 |
| P5 | 1 part P4 + 1 part EIA Diluent | 8.75 |
| P6 | 1 part P5 + 1 part EIA Diluent | 4.375 |
| P7 | 1 part P6 + 1 part EIA Diluent | 2.188 |
| P8 | EIA Diluent | 0.0 |

- Biotinylated Human Complement Factor B Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50fold with EIA Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the
 desired amount of the conjugate 100-fold with EIA Diluent to produce a
 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch

- securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 µl of Human Complement Factor B Standard or sample to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 µl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 µl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human Complement Factor B Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 25 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections.
 Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm

- absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data


The typical data is provided for reference only. Individual laboratory
means may vary from the values listed. Variations between laboratories
may be caused by technique differences.

| Standard Point | ng/ml | OD | Average OD |
|------------------|-----------------|----------------|------------|
| P1 | 140 | 1.829 | 1.818 |
| . – | | 1.807 | |
| P2 | 70 | 1.494 1.450 | 1.472 |
| | 70 | | 1.172 |
| P3 | 35 | 0.972 | 1.003 |
| 13 | 55 | 1.034 | 1.005 |
| P4 | 17.5 | 0.622 | 0.637 |
| Г4 | 17.5 | 0.652 | 0.037 |
| P5 | 8.75 | 0.409 | 0.394 |
| rJ | | 0.379 | 0.334 |
| P6 | 4 275 | 0.254 | 0.244 |
| PO | 4.375 | 0.235 | 0.244 |
| P7 | 2.188 | 0.159 | 0.166 |
| Ρ/ | 2.100 | 0.173 | 0.100 |
| P8 | 0.0 | 0.058 | 0.054 |
| РО | 0.0 | 0.050 | 0.054 |
| Sample: Poo | oled Normal | 0.673 | 0.600 |
| Sodium Citrate I | Plasma (16000x) | 0.711 | 0.692 |
| Sample: Poo | oled Normal | 0.719 | 0.704 |
| Serum (| 16000x) | 0.683 | 0.701 |

Standard Curve

 The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Human Complement Factor B Standard Curve



Reference Value

- Normal human CFB plasma and serum levels range from 200 400 μg/ml.
- Plasma and serum samples from healthy adults were tested (n=40). On average, human CFB level was 296 μg/ml.

| Sample | n | Average Value (μg/ml) |
|----------------------|----|-----------------------|
| Pooled Normal Plasma | 10 | 306 |
| Normal Plasma | 20 | 282 |
| Pooled Normal Serum | 10 | 300 |

Performance Characteristics

- The minimum detectable dose of human CFB as calculated by 2SD from the mean of a zero standard was established to be 0.71 ng/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

| | Intra-Assay Precision | | | Inter-Assay Precision | | |
|-------------------|-----------------------|------|------|-----------------------|-------|-------|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| CV (%) | 6.3% | 5.0% | 4.6% | 9.4% | 10.7% | 10.4% |
| Average CV (%) | | 5.3% | | | 10.2% | |

Recovery

| Standard Added Value | 5 – 70 ng/ml |
|----------------------|--------------|
| Recovery % | 88 – 110% |
| Average Recovery % | 98% |

Linearity

• Plasma and serum samples were serially diluted to test for linearity.

| Average Percentage of Expected Value (%) | | | |
|------------------------------------------|--------|-------|--|
| Sample Dilution | Plasma | Serum | |
| 8000x | 102% | 92% | |
| 16000x | 100% | 103% | |
| 32000x | 97% | 105% | |

Cross-Reactivity

| Species | Cross-Reactivity (%) |
|---------|----------------------|
| Canine | None |
| Bovine | None |
| Equine | None |
| Monkey | <5% |
| Mouse | None |
| Rat | None |
| Swine | None |
| Rabbit | None |

- No significant cross-reactivity observed with complement factor D, factor H, factor I, factor P, C1, C2, C3, C4, C5, C6, C7, C8, and C9.
- 10% FBS in culture media will not affect the assay.

Troubleshooting

| Issue | Causes | Course of Action |
|----------------------------------------------|-------------------------------------------|------------------------------------------------------------------------------------------------------------|
| | Use of improper | Check the expiration date listed before use. |
| | components | Do not interchange components from different lots. |
| | | Check that the correct wash buffer is being used. |
| | | Check that all wells are empty after aspiration. |
| | Improper wash step | Check that the microplate washer is dispensing properly. |
| | | If washing by pipette, check for proper pipetting |
| _ | | technique. |
| Low Precision | Splashing of reagents while loading wells | Pipette properly in a controlled and careful manner. |
| re | Inconsistent volumes | Pipette properly in a controlled and careful manner. |
| ≥ | loaded into wells | Check pipette calibration. |
| | lodded lifto wells | Check pipette for proper performance. |
| _ | Insufficient mixing of | Thoroughly agitate the lyophilized components after |
| | reagent dilutions | reconstitution. |
| | | Thoroughly mix dilutions. |
| | | Check the microplate pouch for proper sealing. |
| | Improperly sealed | Check that the microplate pouch has no punctures. |
| | microplate | Check that three desiccants are inside the microplate |
| | | pouch prior to sealing. |
| _ | Microplate was left | Each step of the procedure should be performed |
| na | unattended between | uninterrupted. |
|) Big | steps | |
| ج | Omission of step Steps performed in | Consult the provided procedure for complete list of steps. |
| Unexpectedly Low or High Signal Intensity | incorrect order | Consult the provided procedure for the correct order. |
| ъ ⊱ | Insufficient amount of | Check pipette calibration. |
| ≥ is | reagents added to | Check pipette for proper performance. |
| ly Low or Intensity | wells | |
| ≟≟ | Wash step was skipped | Consult the provided procedure for all wash steps. |
| Ę | Improper wash buffer | Check that the correct wash buffer is being used. |
| ect | Improper reagent | Consult reagent preparation section for the correct |
| ф× | preparation | dilutions of all reagents. |
| ne | Insufficient or | Consult the provided procedure for correct incubation |
| | prolonged incubation | time. |
| | periods | |
| | | Sandwich ELISA: If samples generate OD values higher the state and and a size (P1) dilute as a sample. |
| ii: | | than the highest standard point (P1), dilute samples further and repeat the assay. |
| ē | Non-optimal sample | Competitive ELISA: If samples generate OD values lower |
| ≦ | dilution | than the highest standard point (P1), dilute samples |
| Ö | anation | further and repeat the assay. |
| <u> </u> | | User should determine the optimal dilution factor for |
| ığ | | samples. |
| Deficient Standard Curve Fit | Contamination of | A new tip must be used for each addition of different |
| S | reagents | samples or reagents during the assay procedure. |
| in in | Contents of wells | Verify that the sealing film is firmly in place before placing |
| Ξ̈́ | evaporate | the assay in the incubator or at room temperature. |
| et | | Pipette properly in a controlled and careful manner. |
| | Improper pipetting | Check pipette calibration. |
| | | Check pipette for proper performance. |

| Insufficient mixing of reagent dilutions | Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions. |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|

References

- (1) Schreiber RD et al. (1978) Proc Natl Acad Sci USA. 75(8):3948-3952.
- (2) Campbell RD, Porter RR. (1983) Proc Natl Acad Sci USA. 80(14):4464-4468.
- (3) Mole JE et al. (1984) J Biol Chem. 259(6):3407-3412.
- (4) Heurich M et al. (2011) Proc Natl Acad Sci USA. 108(21):8761-8766.
- (5) Nakata I et al. (2012) Invest Ophthalmol Vis Sci. 53(2):794-798.

Version 3.8

11